Pluristem Therapeutics Inc.
PLX$113M
Micro CapNASDAQBiological Products, (No Diagnostic Substances)Biotechnology🇺🇸North AmericaHACKENSACK213 employees
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
Drugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
PLX News
Catalyst Timeline
0 upcoming, 0 past
No catalysts found.
Drug Pipeline
PLX-PAD
Hip Fracture
PLX-PAD Low dose
Intermittent Claudication
150M PLX-PAD
Total Hip Arthroplasty
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
PLX-PAD | Phase 3 | Hip Fracture | - | - |
PLX-PAD Low dose | Phase 2 | Intermittent Claudication | - | - |
150M PLX-PAD | Phase 2 | Total Hip Arthroplasty | - | - |
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply